Wedbush downgraded Keros Therapeutics (KROS) to Neutral from Outperform with a $15 price target after removing pulmonary arterial hypertension ...
Geo Group (GEO) commented on a ruling by the U.S. Court of Appeals for the Ninth Circuit in relation to the Nwauzor v. The Geo Group case. Geo ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback